| __timestamp | HUTCHMED (China) Limited | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 205018000 |
| Thursday, January 1, 2015 | 110777000 | 392709000 |
| Friday, January 1, 2016 | 156328000 | 299694000 |
| Sunday, January 1, 2017 | 175820000 | 397061000 |
| Monday, January 1, 2018 | 143944000 | 434100000 |
| Tuesday, January 1, 2019 | 160152000 | 782200000 |
| Wednesday, January 1, 2020 | 188519000 | 1119900000 |
| Friday, January 1, 2021 | 258234000 | 2437500000 |
| Saturday, January 1, 2022 | 311103000 | 1560400000 |
| Sunday, January 1, 2023 | 384447000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Regeneron has consistently outpaced HUTCHMED, with its cost of revenue peaking at approximately $1.82 billion in 2023, a staggering 780% increase from 2014. In contrast, HUTCHMED's cost of revenue grew by 434% over the same period, reaching around $384 million in 2023. This disparity highlights Regeneron's expansive growth and market dominance. However, HUTCHMED's steady increase reflects its strategic positioning in the competitive Chinese market. As the pharmaceutical landscape continues to shift, these insights provide a window into the financial strategies of two key players.
Cost of Revenue: Key Insights for Johnson & Johnson and HUTCHMED (China) Limited
Cost of Revenue Trends: AstraZeneca PLC vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Cost of Revenue Trends: Viatris Inc. vs HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs HUTCHMED (China) Limited
Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Perrigo Company plc and HUTCHMED (China) Limited
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Xencor, Inc.